PER-026-02已完成未知
A MULTI-CENTER STUDY OF 52 WEEKS, RANDOMIZED, DOUBLE-BLIND, DOUBLED MASKED, CONTROLLED WITH PLACEBO AND PARALLEL GROUPS, TO COMPARE THE EFFECTIVENESS AND TOLERABILITY OF THE COMBINATION WITH SALMETEROL / PROPIONATO DE FLUTICASONA (SERETIDE / VIANI / ADV)
GLAXOSMITHKLINE PERU S.A.,0 个研究点目标入组 0 人开始时间: 2002年3月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male or female with an age> 12 years
- •Who are currently receiving b2 short-acting inhaled agonists.
- •That they are able to comply with the therapy and correctly complete the Daily Registration Cards.
- •Have a documented history of asthma for a period of at least 6 months.
排除标准
- •That they have received research medication in the study within 4 weeks prior to the first visit or that they are participating concurrently in another clinical trial.
- •That they are using oral / parenteral corticosteroids or deposit in a period of 12 weeks prior to the first visit.
- •That they are using inhaled corticosteroids within 12 weeks of the first visit.
- •That they are using receptor antagonists for leukotrienes within 12 weeks prior to the first visit.
研究者
相似试验
已完成
Unknown
Efficacy and safety of two hyaluronic acid fillers for the treatment of moderate-to-severe nasolabial folds in a Chinese populatioModerate-to-severe nasolabial folds in Chinese patientsSkin and Connective Tissue DiseasesISRCTN11835676Beijing Tsinghua Chang Gung Hospital339
未知
不适用
A 52-WEEK TREATMENT, MULTI-CENTER, RANDOMIZED, DOUBLEBLIND,DOUBLE DUMMY, PARALLEL-GROUP, ACTIVE CONTROLLEDSTUDY TO COMPARE THE EFFECT OF QVA149 (INDACATEROL MALEATE/ GLYCOPYRRONIUM BROMIDE) WITH SALMETEROL/FLUTICASONE ONTHE RATE OF EXACERBATIONS IN SUBJECTS WITH MODERATE TO VERYSEVERE COPD-J44 Other chronic obstructive pulmonary diseaseOther chronic obstructive pulmonary diseaseJ44PER-068-13OVARTIS BIOSCIENSES PERU S.A.,
已完成
不适用
A 52-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and Open-label Tiotropium (18 μg o.d.) on COPD Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)-J449 Chronic obstructive pulmonary disease, unspecifiedChronic obstructive pulmonary disease, unspecifiedJ449PER-040-10OVARTIS BIOSCIENSES PERU S.A.,31
已完成
不适用
A 52-WEEK, MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRALOKINUMAB IN ADULTS AND ADOLESCENTS WITH ASTHMA INADEQUATELY CONTROLLED ON INHALED CORTICOSTEROID PLUS LONG-ACTING β2-AGONIST (D2210C00007)-J45J45PER-053-14ASTRAZENECA - PERU,101
已完成
不适用
A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg-I10 Essential (primary) hypertensionEssential (primary) hypertensionI10PER-037-04OVARTIS BIOSCIENSES PERU S.A.,